News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

May 7, 2024

Mark Cuban’s Cost Plus Drug Company Partners with RxLink

Author(s):

Mike Hollan

RxLink will incorporate Cost Plus’ prices into its drug pricing platform MedMap.

Stock.adobe.com

Stock.adobe.com

Mark Cuban’s Cost Plus Drug Company continues to expand its partnerships.

RxLink announced that it will be incorporating Cost Plus into its platform.1 MedMap, RxLink’s platform, allows users to use their insurance, third-party discount cards, and manufacturer offers to find and compare drug prices. According to a press release, the addition of Cost Plus to the platform has already accounted for over $162,000 in savings for customers.

In a press release, RxLink’s head of strategic partnerships JB Powell said, “(The relationship is) a natural way for two organizations committed to ensuring access to safe, affordable medicines to work together. There has never been a solution that allows patients to easily understand exactly what their medications will cost before they go to the pharmacy. If we identify ways to reduce out-of-pocket costs, we connect the patient with them automatically; those options would be incomplete without including Cost Plus Drugs' low and transparent pricing. The added benefit is that by working with health systems and other digital health solutions, the savings are delivered by someone they can trust–their doctor."

In the same press release, Mark Cuban’s Cost Plus Drug Company CEO Alex Oshmyansky said, “We are excited to work with RxLink to bring lower prescription drug prices to consumers. Cost Plus Drugs and RxLink share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes."

This is just the latest partnership for Cost Plus. In early May of this year, ScionHealth announced that it would begin making bulk purchases of medications from Cost Plus and delivered to its SafeCor Health SafecorLogics program.2

Safecor Health provides unit-dose drug packing services for hospitals, long-term care providers, pharmaceutical manufacturers, and retail & digital health companies.

In a press release issued at the time, ScionHealth’s CEO Rob Jay said, “Across the industry and particularly in hospital settings, we are facing the challenges of rising drug and supply costs and navigating staffing shortages. ScionHealth is continually looking for innovative approach to address these issues while continuing to advance the delivery of high-quality, patient-centered care and wellbeing to our communities. SafecorLogics has already been an effective solution to help us address these challenges. Now, by introducing Cost Plus Drugs, we are confident we'll see even more success managing drug costs and enhancing care delivery across the ScionHealth network."

In April of this year, Price.com also announced a partnership with Cost Plus.3 As part of the partnership, Cost Plus’ pricing has been integrated into Price.com’s platform.

At the time, Oshmyanksky said in a press release, “We are thrilled to collaborate with Price.com in our mission to make prescription drugs more affordable for consumers. At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with Price.com, we are dedicated to providing affordable and accessible healthcare solutions for all."

Price.com founder and CEO RJ Jain added, “Teaming up with Mark Cuban Cost Plus Drug Company is a pivotal step towards achieving our shared goal of improving healthcare affordability and accessibility. Thanks to this collaboration, Price.com users can make informed choices that best suit their health and financial needs."

Sources

  1. Mark Cuban Cost Plus Drug Company Teams Up with RxLink to Bring Pharmacy Cost Transparency to Patients of Leading Health Systems. RxLink Inc. May 7, 2024. https://www.prnewswire.com/news-releases/mark-cuban-cost-plus-drug-company-teams-up-with-rxlink-to-bring-pharmacy-cost-transparency-to-patients-of-leading-health-systems-302137468.html
  2. Mark Cuban Cost Plus Drug Company to Supply ScionHealth Utilizing Safecor Health Program. Safecor Health. May 1, 2024. Accessed May 7, 2024. https://www.prnewswire.com/news-releases/mark-cuban-cost-plus-drug-company-to-supply-scionhealth-utilizing-safecor-health-program-302133476.html
  3. Price.com Announces Collaboration with Mark Cuban Cost Plus Drug Company to Make Prescription Drugs More Affordable. Price.com. April 2, 2024. Accessed May 7, 2024. https://www.prnewswire.com/news-releases/pricecom-announces-collaboration-with-mark-cuban-cost-plus-drug-company-to-make-prescription-drugs-more-affordable-302105807.html

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Derrick Gastineau
Noah Nasser
Related Content
Advertisement
Stock.adobe.com
August 28th 2025

Replicate Bioscience Announces Partnership with Novo Nordisk Aimed at Unlocking Self-Replicating RNA Therapies

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 28th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Robert F. Kennedy Jr.
August 28th 2025

Susan Monarez Rejects Removal as CDC Director Even After White House Steps In

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 28th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 28th 2025

FDA Accepts New Drug Application for Gadoquatrane

Nicholas Jacobus
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 28th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
Related Content
Advertisement
Stock.adobe.com
August 28th 2025

Replicate Bioscience Announces Partnership with Novo Nordisk Aimed at Unlocking Self-Replicating RNA Therapies

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 28th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Robert F. Kennedy Jr.
August 28th 2025

Susan Monarez Rejects Removal as CDC Director Even After White House Steps In

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 28th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 28th 2025

FDA Accepts New Drug Application for Gadoquatrane

Nicholas Jacobus
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 28th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.